drugset / Trial / NCT06535399

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

NCT06535399

Phase 1 Completed 29 enrolled Celgene Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.

Timeline

Start
2024-08-15
Primary completion
2025-11-12
Completion
2025-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Golcadomide Other / unclassified

Indications

No indication recorded.